慢性疼痛市场按药物类别、适应症、用途、分销管道和地区划分

2025 年全球慢性疼痛市场规模估计为 773 亿美元，预计到 2032 年将达到 1,258.4 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.2%。

图。

慢性疼痛是指持续超过三个月或已超过正常癒合期的疼痛。许多疾病会引起慢性疼痛，包括关节炎、背痛、癌症、神经系统疾病和纤维肌痛。久坐的生活方式和日益增加的慢性疾病可能会增加全世界慢性疼痛的盛行率。慢性疼痛会限制活动能力和日常功能，对生活品质产生负面影响。全球慢性疼痛市场包括疼痛管理药物、神经调节设备和其他治疗方式，以减轻患者的痛苦并改善患者的治疗效果。患有此类疾病的老年人口快速增加、医疗支出增加、新产品推出以及对管理选择的认识不断提高是推动市场成长的因素。

市场动态

慢性疾病和伤害的日益普及是导致全球慢性疼痛发病率上升的主要原因。这包括骨关节炎和背痛等肌肉骨骼疾病。易患此类疾病的老年人口不断增加，将推动市场成长。此外，医疗支出的增加、新产品创新以及付款昂贵治疗方案的能力也将推动市场成长。然而，学名药等替代品的存在、违规以及某些治疗方法的副作用可能会对市场参与企业造成挑战。此外，新产品核可的监管障碍也可能阻碍市场成长。新兴经济体为产业参与企业提供了巨大的机会。疼痛治疗方法技术的进步可能为市场成长开闢新的途径。

研究的主要特点

本报告对全球慢性疼痛市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设基准年为 2024 年。

它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

全球慢性疼痛市场的主要企业是根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行的分析。

研究涉及的主要企业包括辉瑞、礼来、葛兰素史克、诺华、强生、阿斯特捷利康、普渡製药、Endo Pharmaceuticals、Teva Pharmaceuticals Industries Ltd. 和 Mallinckrodt Pharmaceuticals。

本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。

全球慢性疼痛市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员将透过全球慢性疼痛市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购情景

4. 2020 年至 2032 年全球慢性疼痛市场（按药物类别划分）（十亿美元）

• 介绍
• 阿片类药物
• 非类固醇消炎剂(NSAID)
• 抗惊厥药
• 抗忧郁症
• 其他的

5. 2020 年至 2032 年全球慢性疼痛市场（按适应症划分）（十亿美元）

• 介绍
• 神经病变疼痛
• 关节炎疼痛
• 慢性背痛
• 癌症痛
• 偏头痛
• 纤维肌痛
• 其他的

6. 2020 年至 2032 年全球慢性疼痛市场（按应用划分）（十亿美元）

• 介绍
• 肌肉骨骼
• 神经病变
• 肿瘤学
• 其他的

7. 2020 年至 2032 年按分销管道分類的全球慢性疼痛市场（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年全球慢性疼痛市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline PLC
• Bayer AG
• Novartis AG
• Endo Pharmaceuticals
• Bristol-Myers Squibb
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Medtronic plc
• AstraZeneca PLC
• Becton, Dickinson and Company
• AbbVie Inc.
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals
• Zynerba Pharmaceuticals
• Neurocrine Biosciences
• Sorrento Therapeutics
• Cypress Pharmaceutical

第 10 章分析师建议

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Chronic Pain Market is estimated to be valued at USD 77.30 Bn in 2025 and is expected to reach USD 125.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Figure. Chronic Pain Market Share (%), By Region 2025

Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.

Market Dynamics:

Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.

Key features of the study:

This report provides in-depth analysis of the global chronic pain market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market

Detailed Segmentation-

• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Opioids
  • Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Anticonvulsants
  • Antidepressants
  • Others
• By Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Neuropathic pain
  • Arthritis pain
  • Chronic back pain
  • Cancer pain
  • Migraine
  • Fibromyalgia
  • Others
• By Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Musculoskeletal
  • Neuropathy
  • Oncology
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Bayer AG
  • Novartis AG
  • Endo Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc
  • Medtronic plc
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • AbbVie Inc.
  • Horizon Therapeutics
  • Mallinckrodt Pharmaceuticals
  • Zynerba Pharmaceuticals
  • Neurocrine Biosciences
  • Sorrento Therapeutics
  • Cypress Pharmaceutical

Table of Contents

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

• Research Objectives
• Assumptions
• Abbreviations

2. MARKET PURVIEW

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Chronic Pain Market, By Drug Class
  • Global Chronic Pain Market, By Indication
  • Global Chronic Pain Market, By Application
  • Global Chronic Pain Market, By Distribution Channel
  • Global Chronic Pain Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Chronic Pain Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Opioids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Chronic Pain Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Neuropathic pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Arthritis pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Chronic back pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Migraine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fibromyalgia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Pain Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Musculoskeletal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Pain Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Pain Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Endo Pharmaceuticals
• Bristol-Myers Squibb
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Medtronic plc
• AstraZeneca PLC
• Becton, Dickinson and Company
• AbbVie Inc.
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals
• Zynerba Pharmaceuticals
• Neurocrine Biosciences
• Sorrento Therapeutics
• Cypress Pharmaceutical

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us